about
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Gout: optimizing treatment to achieve a disease cure2016 updated EULAR evidence-based recommendations for the management of gout.Synovial fluid analysis for diagnosis of intercritical gout.Most calcium pyrophosphate crystals appear as non-birefringentSynovial fluid analysis.An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.EULAR recommendations for calcium pyrophosphate deposition. Part II: management.Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluidUrinary albumin excretion in patients with systemic lupus erythematosus without renal diseaseIntracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy.Gout, diuretics and the kidney."Crystal clear"-sonographic assessment of gout and calcium pyrophosphate deposition disease.Therapeutic advances in gout.EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee.International position paper on febuxostat.European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.Gout: why is this curable disease so seldom cured?Improving cardiovascular and renal outcomes in gout: what should we target?Mechanisms of crystal formation in gout-a structural approach.Current advances in therapies for calcium pyrophosphate crystal arthritis.Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register.Understanding How the Diagnostic Delay of Spondyloarthritis Differs Between Women and Men: A Systematic Review and Metaanalysis.Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment.Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.Analysis for crystals in synovial fluid: training of the analysts results in high consistency.Shoes and lower limb osteoarthritis.Chronic pancreatitis associated with systemic lupus erythematosus in a young girl.Sex and Gender Interactions in the Lives of Patients with Spondyloarthritis in Spain: A Quantitative-qualitative Study.Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study.Clinical Images: Hematoidin in Synovial Fluid.Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan.Managing Gout in the Patient with Renal Impairment.Survival analysis of 306 European Spanish patients with systemic lupus erythematosus.Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?Impaired Trunk Posture In Women With Fibromyalgia.Gout mimicking rheumatoid arthritis.Back pain due to lumbar gouty flare--a prospective diagnosis.
P50
Q24675150-70492104-D520-4591-8C12-7FD0636815F9Q26765550-2E6C9C33-7AAD-49FD-B5A2-736CAE9C5F3EQ30248787-D1451642-75E5-4F74-A8D1-A52119F32168Q30639736-C74BCE60-F946-4C71-977B-5920E54FC7C0Q30758772-6469FE05-86B2-4CDA-BBE0-D41643727C4FQ33216566-00F2265E-5087-4E2D-9B49-0CC195759A6EQ34030277-ABADD88A-B411-4D68-9201-BA6DD7DE0047Q34626526-C803B94D-9F40-4992-8D39-BBE5E98E9EADQ35232958-D32C68C5-C90D-459B-88DA-AE65D50B85D3Q35544188-ABCB2F74-1181-49DE-B504-46EF973F8FE6Q35547291-6563013C-E40E-49F9-9E8C-01A1D01A18BDQ35555087-3144D1DE-D42C-4C64-9F19-66F32027CCE8Q35637470-D9182790-B5D1-4937-AC8B-74F65C88C596Q36608517-0071BFF3-BD27-4271-8A89-5939B9334409Q36728463-48D8B95D-3841-4613-94CF-9EB8358DFDBFQ37369605-FA6C8CA3-5559-4A6A-B541-4EAAC7676172Q37733344-94564820-3117-4BE1-B300-883083949961Q37827003-EFE9019D-263C-4D55-AC91-46EFF25CEB8DQ38032068-4C01A8E0-3C26-449B-AE63-06EDF567C7AAQ38241233-553A8E78-E68F-4740-A945-9B829DC77246Q38586640-4FC6C4A4-1390-4F17-9238-735B4ABE1599Q38701148-BF39C7D5-B109-47E7-B3D6-9254AD9904E8Q38907911-198D6A26-69E7-45C2-BB10-FBB0262F0626Q39040219-BFB8272C-CCC2-45B5-99EA-4E2A0A8FE43DQ40378504-4FE5C435-8092-443F-A564-5EE319B96310Q41970890-24FA2BE6-4579-4655-85B5-8602B4A48828Q42792233-E77C898B-9690-4A24-968D-AC46910D66A9Q43079308-D5550435-294C-44FA-954A-BE307B34B10AQ44595475-A87F4A2D-0D3B-4118-A4AE-ECBD9D698BCDQ47332186-5E24B0B3-94A5-499B-BF80-E96A411D4EB1Q48209584-4F1E53E9-03AE-4C43-B957-11CB27BD4C09Q48265903-041E1C2D-BED5-464B-B925-C59241E16B62Q48353144-D7871AF4-8DC0-4411-8EB7-0A6AB132B8A1Q49927288-2B71D65D-726A-41D4-8B01-1832E656826BQ50050773-815E717F-DD6E-4B67-8317-7DB2D526A83AQ50885213-68E73575-B6AB-4521-926A-8BF2B4160AC8Q53119881-6DAA1F40-EF91-4800-BFF5-D149A2BED775Q53411441-7AD47411-BF78-4958-BA45-6410F49A2DC5Q53748495-FC2B2A24-D44F-49C3-88FB-821B81D45751Q54363848-E4889AC8-13F6-4E05-BB6D-5286EA174C82
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
E Pascual
@ast
E Pascual
@en
E Pascual
@es
E Pascual
@nl
type
label
E Pascual
@ast
E Pascual
@en
E Pascual
@es
E Pascual
@nl
prefLabel
E Pascual
@ast
E Pascual
@en
E Pascual
@es
E Pascual
@nl
P106
P1153
57201567089
P31
P496
0000-0002-3056-4478